MDT-AP-2796
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 9.84
- os_event
- false
- age_years
- 3.9
- sex
- M
- new_clusters
- C4
- umap1_2d
- 2.936098042
- umap2_2d
- 3.438090295
- umap1_3d
- 0.345331853
- umap2_3d
- -1.346842051
- umap3_3d
- -1.650969728
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INFLAMMATORY_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.480
- IL6_JAK_STAT3_SIGNALING+0.470
- KRAS_SIGNALING_UP+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- TNFA_SIGNALING_VIA_NFKB+0.430
- INTERFERON_ALPHA_RESPONSE+0.420
- UV_RESPONSE_DN+0.420
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.440
- DNA_REPAIR-0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- MYC_TARGETS_V1-0.310
- FATTY_ACID_METABOLISM-0.240
- MYC_TARGETS_V2-0.240
- PEROXISOME-0.210
- WNT_BETA_CATENIN_SIGNALING-0.200
- ADIPOGENESIS-0.170
- UV_RESPONSE_UP-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.876 |
| 2 | TCGA-E2-A1B1-01A-21R-A12P-07 | — | A | 0.876 |
| 3 | c56e13bb-f1b0-4ee3-85c1-807c7c3bcef9 | — | — | 0.874 |
| 4 | TCGA-CN-5370-01A-01R-2016-07 | — | — | 0.873 |
| 5 | EPT0805 | EPN | Posterior Fossa EPN | 0.873 |
| 6 | s_150203_5b | EPN | Posterior Fossa EPN | 0.872 |
| 7 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.869 |
| 8 | aad90266-d469-4986-b260-d0df4c2f48e7 | — | — | 0.865 |
| 9 | MNG3 | — | — | 0.860 |
| 10 | 6a43f966-cb2b-47ee-b0f4-c269707daa88 | — | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |